tatton: osimertinib plus savolitinib for patients with egfr-mutant, met-amplified nsclc after pr...
Published 5 years ago • 269 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
4:49
tatton trial – savolitinib plus osimertinib in egfr-mutated, met-amplified nsclc | lecia sequist
-
9:25
tatton: updated results for patients with egfr-mutant positive nsclc
-
2:02
understanding egfr resistance in patients with met-amplified nsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
4:50
tatton: phase 1b trial of azd9291 for egfr-mutant lung cancer
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
0:48
new standard of care for lung cancer patients with egfr mutations
-
5:52
treatment of egfr nsclc after osimertinib
-
2:21
treatment of egfr nsclc after progression
-
3:54
teslisotuzumab vedotin and osimertinib for egfr-mutant, c-met-overexpressing nsclc
-
9:02
amivantamab plus lazertinib for egfr-mutant lung cancer following progression on osimertinib
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
5:52
mechanisms of osimertinib resistance in aura 3
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc